James Z Deng

Dr. James Z Deng

orcid

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 December 2008 in Organic Letters
Verified
Journal Article
Closed access
JDJames Z Deng
James Z Deng
DPDaniel V. Paone
Daniel V. Paone
AGAnthony T. Ginnetti
Anthony T. Ginnetti
HKHideki Kurihara
Hideki Kurihara
SDSpencer D. Dreher
Spencer D. Dreher
CBChristopher S. Burgey
Christopher S. Burgey

6 February 2022 in Vaccine
Verified
Journal Article
Open access
JDJames Z Deng
James Z Deng
CLCatherine Lancaster
Catherine Lancaster
MWMichael A. Winters
Michael A. Winters
KPKatherine M. Phillips
Katherine M. Phillips
PZPing Zhuang
Ping Zhuang
SHSha Ha
Sha Ha
Streptococcus pneumoniae bacterial infection can cause serious diseases. Among more than 90 known streptococcus pneumoniae serotypes, more than 30 can cause invasive pneumococcal diseases that could lead to morbidity and mortality. Initially, a 23-valent polysaccharide vaccines (PPSV) PNEUMOVAX®23, was developed to generate an antigen-specific immune response and prevent diseases caused by these pneumoniae serotypes. Later, pneumococcal conjugate vaccines (PCV), such as PREVNAR® and VAXNEUVANCE™ have been developed to offer a more robust immune response in the pediatric population. In our effort to develop novel pneumococcal conjugate vaccines, each serotype of pneumococcal polysaccharide (Ps) is conjugated to a detoxified diphtheria toxin carrier protein CRM197 to form a monovalent conjugate (MVC). MVCs from multiple serotypes are formulated with vaccine adjuvant to form a multi-valent vaccine drug product. During the product development, critical attributes including conjugate molecular weight (Mw), protein and polysaccharide concentration, have been used to monitor process and product quality. To measure these attributes, a size-exclusion chromatography (SEC) method was developed with a series of in-line detectors including UV, multi-angle light scattering (MALS) and refractive index (RI). This SEC-UV-MALS-RI method is employed to characterize and monitor process intermediates and product during process development and for product release and stability testing. With this, we have expanded the multi-attribute SEC method to a 15-valent pneumococcal conjugate vaccine.

9 September 2022 in Polymers
Verified
Journal Article
Open access
PDF file
JDJames Z Deng
James Z Deng
JLJason Lin
Jason Lin
MCMichelle Chen
Michelle Chen
CLCatherine Lancaster
Catherine Lancaster
PZPing Zhuang
Ping Zhuang
Infections by Streptococcus pneumoniae can cause serious pneumococcal diseases and other medical complications among patients. Polysaccharide-based vaccines have been successfully developed as prophylactic agents against such deadly bacterial infections. In the 1980s, PNEUMOVAX® 23 were introduced as the first pneumococcal polysaccharide vaccines (PPSV). Later, pneumococcal polysaccharides were conjugated to a carrier protein to improve immune responses. Pneumococcal conjugate vaccines (PCV) such as PREVNAR® and VAXNEUVANCE™ have been developed. Of the more than 90 pneumococcal bacteria serotypes, serotype 1 (ST-1) and serotype 4 (ST-4) are the two main types that cause invasive pneumococcal diseases (IPD) that could lead to morbidity and mortality. Development of a novel multi-valent PCV against these serotypes requires extensive biophysical and biochemical characterizations of each monovalent conjugate (MVC) in the vaccine. To understand and characterize these high molecular weight (Mw) polysaccharide protein conjugates, we employed the multi-angle light scattering (MALS) technique coupled with size-exclusion chromatography (SEC) separation and asymmetrical flow field flow fractionation (AF4). MALS analysis of MVCs from the two orthogonal separation mechanisms helps shed light on the heterogeneity in conformation and aggregation states of each conjugate.

29 September 2005 in Tetrahedron Letters
Verified
Journal Article
Closed access
JDJames Z Deng
James Z Deng
CBChristopher S. Burgey
Christopher S. Burgey

1 May 2018 in Bioorganic & Medicinal Chemistry Letters
Verified
Journal Article
Closed access
AGAnthony T. Ginnetti
Anthony T. Ginnetti
DPDaniel V. Paone
Daniel V. Paone
SSShaun R. Stauffer
Shaun R. Stauffer
CPCraig M. Potteiger
Craig M. Potteiger
ASAnthony W. Shaw
Anthony W. Shaw
CBChristopher S. Burgey
Christopher S. Burgey

11 December 2021 in Molecular Therapy-Oncolytics
Verified
Journal Article
Open access
JDJames Z Deng
James Z Deng
RRRichard R. Rustandi
Richard R. Rustandi
ASAndrew Swartz
Andrew Swartz
YSYvonne Shieh
Yvonne Shieh
JBJack B. Baker
Jack B. Baker
JLJohn W. Loughney
John W. Loughney
V937 is an oncolytic virus immunotherapy clinical drug candidate consisting of a proprietary formulation of Coxsackievirus A21 (CVA21). V937 specifically binds to and lyses cells with over-expressed ICAM-1 receptors in a range of tumor cell types and is currently in phase I and II clinical trials. Infectious V937 particles consist of a ∼30 nm icosahedral capsid assembled from four structural viral proteins that encapsidate a viral RNA genome. Rapid and robust analytical methods to quantify and characterize CVA21 virus particles are important to support the process development, regulatory requirements, and validation of new manufacturing platforms. Herein, we describe a size-exclusion chromatography (SEC) method that was developed to characterize the V937 drug substance and process intermediates. Using a 4-in-1 combination of multi-detectors (UV, refractive index, dynamic and static light scattering), we demonstrate the use of SEC for the quantification of the virus particle count, the determination of virus size (molecular weight and hydrodynamic diameter), and the characterization of virus purity by assessing empty-to-full capsid ratios. Through a SEC analysis of stressed V937 samples, we propose CVA21 thermal degradation pathways that result in genome release and particle aggregation.